| Characteristics . | Values . |
|---|---|
| Female, n (%) | 460 (92%) |
| Age at diagnosis, years, mean (s.d.) | 40.7 (21.0) |
| Disease duration at enrolment, years, mean (s.d.) | 10.8 (9.9) |
| Age at enrolment, years, mean (s.d.) | 50.4 (13.7) |
| SLICC 2012 criteria (ever present) | |
| Clinical criteria, n (%) | |
| Acute cutaneous lupus | 262 (51.57) |
| Chronic cutaneous lupus | 57 (11.22) |
| Oral or nasal ulcers | 171 (33.66) |
| Non-scaring alopecia | 156 (30.71) |
| Arthritis | 355 (69.88) |
| Serositis | 96 (18.9) |
| Renal | 158 (31.1) |
| Neurologic | 32 (6.3) |
| Haemolytic anaemia | 29 (5.7) |
| Leukopenia | 219 (43.11) |
| Thrombocytopenia | 88 (17.3) |
| Immunological criteria, n (%) | |
| ANA | 489 (96.26) |
| Anti-dsDNA antibodies | 329 (64.76) |
| Anti-Sm antibodies | 95 (18.7) |
| Anti-phospholipid antibodies | 163 (32.09) |
| Low complement levels | 306 (60.24) |
| Number of SLICC criteria for SLE, n (%) | 6.2 (2.2) |
| SLEDAI-2K score at enrolment, mean (s.d.) | 2.8 (3.3) |
| SLICC/ACR-DI score at enrolment mean (s.d.) | 0.96 (1.4) |
| Damage present at enrolment, n (%) | 253 (49.8) |
| Clinical SLEDAI-2K score, mean (s.d.) | 1.6 (2.7) |
| Current hypocomplementemia, n (%) | 152 (29.9) |
| Current elevated anti-dsDNA, n (%) | 125 (24.6) |
| PGA at enrolment, mean (s.d.) | 0.2 (0.49) |
| Characteristics . | Values . |
|---|---|
| Female, n (%) | 460 (92%) |
| Age at diagnosis, years, mean (s.d.) | 40.7 (21.0) |
| Disease duration at enrolment, years, mean (s.d.) | 10.8 (9.9) |
| Age at enrolment, years, mean (s.d.) | 50.4 (13.7) |
| SLICC 2012 criteria (ever present) | |
| Clinical criteria, n (%) | |
| Acute cutaneous lupus | 262 (51.57) |
| Chronic cutaneous lupus | 57 (11.22) |
| Oral or nasal ulcers | 171 (33.66) |
| Non-scaring alopecia | 156 (30.71) |
| Arthritis | 355 (69.88) |
| Serositis | 96 (18.9) |
| Renal | 158 (31.1) |
| Neurologic | 32 (6.3) |
| Haemolytic anaemia | 29 (5.7) |
| Leukopenia | 219 (43.11) |
| Thrombocytopenia | 88 (17.3) |
| Immunological criteria, n (%) | |
| ANA | 489 (96.26) |
| Anti-dsDNA antibodies | 329 (64.76) |
| Anti-Sm antibodies | 95 (18.7) |
| Anti-phospholipid antibodies | 163 (32.09) |
| Low complement levels | 306 (60.24) |
| Number of SLICC criteria for SLE, n (%) | 6.2 (2.2) |
| SLEDAI-2K score at enrolment, mean (s.d.) | 2.8 (3.3) |
| SLICC/ACR-DI score at enrolment mean (s.d.) | 0.96 (1.4) |
| Damage present at enrolment, n (%) | 253 (49.8) |
| Clinical SLEDAI-2K score, mean (s.d.) | 1.6 (2.7) |
| Current hypocomplementemia, n (%) | 152 (29.9) |
| Current elevated anti-dsDNA, n (%) | 125 (24.6) |
| PGA at enrolment, mean (s.d.) | 0.2 (0.49) |
| Characteristics . | Values . |
|---|---|
| Female, n (%) | 460 (92%) |
| Age at diagnosis, years, mean (s.d.) | 40.7 (21.0) |
| Disease duration at enrolment, years, mean (s.d.) | 10.8 (9.9) |
| Age at enrolment, years, mean (s.d.) | 50.4 (13.7) |
| SLICC 2012 criteria (ever present) | |
| Clinical criteria, n (%) | |
| Acute cutaneous lupus | 262 (51.57) |
| Chronic cutaneous lupus | 57 (11.22) |
| Oral or nasal ulcers | 171 (33.66) |
| Non-scaring alopecia | 156 (30.71) |
| Arthritis | 355 (69.88) |
| Serositis | 96 (18.9) |
| Renal | 158 (31.1) |
| Neurologic | 32 (6.3) |
| Haemolytic anaemia | 29 (5.7) |
| Leukopenia | 219 (43.11) |
| Thrombocytopenia | 88 (17.3) |
| Immunological criteria, n (%) | |
| ANA | 489 (96.26) |
| Anti-dsDNA antibodies | 329 (64.76) |
| Anti-Sm antibodies | 95 (18.7) |
| Anti-phospholipid antibodies | 163 (32.09) |
| Low complement levels | 306 (60.24) |
| Number of SLICC criteria for SLE, n (%) | 6.2 (2.2) |
| SLEDAI-2K score at enrolment, mean (s.d.) | 2.8 (3.3) |
| SLICC/ACR-DI score at enrolment mean (s.d.) | 0.96 (1.4) |
| Damage present at enrolment, n (%) | 253 (49.8) |
| Clinical SLEDAI-2K score, mean (s.d.) | 1.6 (2.7) |
| Current hypocomplementemia, n (%) | 152 (29.9) |
| Current elevated anti-dsDNA, n (%) | 125 (24.6) |
| PGA at enrolment, mean (s.d.) | 0.2 (0.49) |
| Characteristics . | Values . |
|---|---|
| Female, n (%) | 460 (92%) |
| Age at diagnosis, years, mean (s.d.) | 40.7 (21.0) |
| Disease duration at enrolment, years, mean (s.d.) | 10.8 (9.9) |
| Age at enrolment, years, mean (s.d.) | 50.4 (13.7) |
| SLICC 2012 criteria (ever present) | |
| Clinical criteria, n (%) | |
| Acute cutaneous lupus | 262 (51.57) |
| Chronic cutaneous lupus | 57 (11.22) |
| Oral or nasal ulcers | 171 (33.66) |
| Non-scaring alopecia | 156 (30.71) |
| Arthritis | 355 (69.88) |
| Serositis | 96 (18.9) |
| Renal | 158 (31.1) |
| Neurologic | 32 (6.3) |
| Haemolytic anaemia | 29 (5.7) |
| Leukopenia | 219 (43.11) |
| Thrombocytopenia | 88 (17.3) |
| Immunological criteria, n (%) | |
| ANA | 489 (96.26) |
| Anti-dsDNA antibodies | 329 (64.76) |
| Anti-Sm antibodies | 95 (18.7) |
| Anti-phospholipid antibodies | 163 (32.09) |
| Low complement levels | 306 (60.24) |
| Number of SLICC criteria for SLE, n (%) | 6.2 (2.2) |
| SLEDAI-2K score at enrolment, mean (s.d.) | 2.8 (3.3) |
| SLICC/ACR-DI score at enrolment mean (s.d.) | 0.96 (1.4) |
| Damage present at enrolment, n (%) | 253 (49.8) |
| Clinical SLEDAI-2K score, mean (s.d.) | 1.6 (2.7) |
| Current hypocomplementemia, n (%) | 152 (29.9) |
| Current elevated anti-dsDNA, n (%) | 125 (24.6) |
| PGA at enrolment, mean (s.d.) | 0.2 (0.49) |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
